{"id":241805,"date":"2026-05-08T13:03:00","date_gmt":"2026-05-08T17:03:00","guid":{"rendered":"https:\/\/news-you-need.com\/index.php\/2026\/05\/08\/gilead-posts-positive-q1-buoyed-by-hiv-drug-growth\/"},"modified":"2026-05-08T13:30:11","modified_gmt":"2026-05-08T17:30:11","slug":"gilead-posts-positive-q1-buoyed-by-hiv-drug-growth","status":"publish","type":"post","link":"https:\/\/news-you-need.com\/index.php\/2026\/05\/08\/gilead-posts-positive-q1-buoyed-by-hiv-drug-growth\/","title":{"rendered":"Gilead posts positive Q1 buoyed by HIV drug growth"},"content":{"rendered":"<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/gilead-sciences-q1-results-hiv-biktarvy-yeztugo\/\">Gilead posts positive Q1 buoyed by HIV drug growth<\/a><\/p>\n<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/gilead-sciences-q1-results-hiv-biktarvy-yeztugo\/\">https:\/\/www.pharmaceutical-technology.com\/news\/gilead-sciences-q1-results-hiv-biktarvy-yeztugo\/<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-05-08 13:03:00<\/a><\/p>\n<p>Source Domain: <a href=\"www.pharmaceutical-technology.com\">www.pharmaceutical-technology.com<\/a><\/p>\n<p>                                    Gilead\u2019s HIV portfolio was a strong growth area for the company in Q1 2026. Credit: Tada Images \/ Shutterstock.com.<\/p>\n<p class=\"drop-cap\">Gilead Sciences has secured a good start to 2026 with its human immunodeficiency (HIV) medicines amid the backdrop of a generally positive first quarter.<\/p>\n<p>During Q1 2026, Gilead\u2019s total revenue took a 4% upturn year-on-year (YoY) to $7bn, exceeding the analyst consensus. Of the $6.9bn in total product sales recorded during this period, $5bn was brought in by the company\u2019s HIV portfolio, which grew by 10% YoY.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/img\/globaldata_marketing_solutions_logo.svg\" alt=\"\"\/><\/p>\n<h4> Discover B2B Marketing That Performs <\/h4>\n<p>\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n<p>\n\t\t\t\t\t\t\tFind out more <span><\/span><\/p>\n<p>Gilead\u2019s sales uptick was primarily driven by the ballooning trade of its daily HIV pill, Biktarvy (bictegravir\/emtricitabine\/tenofovir alafenamide), which brought in $3.36bn globally in Q1, trumping the $3.15bn made in 2025.<\/p>\n<p>While the three-drug regimen is currently the top-selling HIV medicine, commanding more than half the indication\u2019s overall sales share, new market arrivals are now making their way to patients. This includes MSD\u2019s two-drug, no integrase strand transfer inhibitor (INSTI)-reliant regimen, Idvynso (doravirine\/islatravir), which secured US regulatory approval in April 2026.<\/p>\n<p>GlobalData analyst, Anaelle Tannen, previously told Pharmaceutical Technology that Idvynso\u2019s approval reflects a broader shift in the HIV treatment landscape away from traditional three-drug combinations&#8230;<\/p>\n<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/gilead-sciences-q1-results-hiv-biktarvy-yeztugo\/\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead posts positive Q1 buoyed by HIV drug growth https:\/\/www.pharmaceutical-technology.com\/news\/gilead-sciences-q1-results-hiv-biktarvy-yeztugo\/ Publish Date: 2026-05-08 13:03:00 Source&#8230;<\/p>\n","protected":false},"author":1,"featured_media":241806,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.pharmaceutical-technology.com\/wp-content\/uploads\/sites\/24\/2026\/05\/shutterstock_1667251990-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[8],"tags":[],"class_list":["post-241805","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/241805"}],"collection":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=241805"}],"version-history":[{"count":1,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/241805\/revisions"}],"predecessor-version":[{"id":241807,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/241805\/revisions\/241807"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/241806"}],"wp:attachment":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=241805"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=241805"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=241805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}